Julia P. Gregory - 14 Oct 2026 Form 4 Insider Report for Nurix Therapeutics, Inc. (NRIX)

Reporting relationship: Director
Issuer ticker: NRIX
Reported as of: 14 Oct 2026
Net transaction value: -$528,528
SEC form: 4
Accepted by SEC: 14 Oct 2026, 16:11:39 UTC
Prior SEC filing: 15 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Daniel Burbach, as Attorney-in-Fact for Julia P. Gregory

Filing notes and source

Key filing fact

Julia P. Gregory filed Form 4 for Nurix Therapeutics, Inc. (NRIX) on 14 Oct 2026.

Key facts

This page summarizes Julia P. Gregory's Form 4 filing for Nurix Therapeutics, Inc. (NRIX).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 14 Oct 2026, 16:11.

Change

Previous filing in this sequence was filed on 15 May 2026.
Current net transaction value: -$528,528.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001226675 Primary reporting owner

GREGORY JULIA P

Relationship: Director
Address: C/O NURIX THERAPEUTICS, INC., 1600 SIERRA POINT PKWY, BRISBANE
Signature: /s/ Daniel Burbach, as Attorney-in-Fact for Julia P. Gregory
Signature date: 14 Oct 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NRIX transaction

Common Stock

Options Exercise

Transaction value
Shares: +22,583
Change %: +210%
Price: $1.86^*
Shares after: 33,333
Date: 14 Oct 2026
Ownership: Direct

NRIX transaction

Common Stock

Sale

Transaction value: $528,528
Shares: -22,583
Change %: -68%
Price: $23.40
Shares after: 10,750
Date: 14 Oct 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

NRIX transaction Derivative

Director Stock Option (right to buy)

Options Exercise

Transaction value
Shares: -22,583
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 14 Oct 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 22,583
Exercise price: $1.86
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents the weighted average sale price. The lowest price at which shares were sold was $23.34 and the highest price at which shares were sold was $23.62. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

Footnote F2

The stock option vested as to 1/48 of the total shares monthly beginning September 12, 2019 until the option was fully vested on August 12, 2023.